Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Endocrine disorders – page 22

  • 497 clinical trials
  • 183 recruiting
  • 211 conditions
  • 25 countries

Conditions in this area

211 conditions with trials, the busiest first

Type 2 diabetes mellitus83Type 1 diabetes mellitus38Endocrine ophthalmopathy26Neuroblastoma26Obesity22Diabetes mellitus21Neuroendocrine tumour19Gastroenteropancreatic neuroendocrine tumour disease16Overweight16Diabetic foot13Diabetic retinal oedema13Diabetic neuropathy12Myotonic dystrophy12Adrenogenital syndrome11Neuroendocrine carcinoma11Thyroid cancer11Graves' disease10Hypoparathyroidism9Acromegaly8Chronic kidney disease8Adrenoleukodystrophy7Glucose tolerance impaired7Pancreatic neuroendocrine tumour7Adrenocortical carcinoma6+187

Clinical trials in Endocrine disorders

497 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

497 clinical trials

Thyroidectomy+1

Not yet recruiting

Study on Using Indocyanine Green to Protect Parathyroid Glands During Thyroid Surgery for Patients with Hypothyroidism

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Indocyanine Green
  • Sponsor:Bellvitge University Hospital

Neuroblastoma

Not yet recruiting

Study of ABTL0812 with Irinotecan and Temozolomide for Children with Relapsed or Refractory Neuroblastoma and Other Solid Tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Sodium 2-Hydroxylinoleate
  • Sponsor:Fir Huvh Fundacio Institut De Recerca Hospital Universitari Vall De Hebron

Small fibre neuropathy

Not yet recruiting

Study on the Effect of Human Normal Immunoglobulin and Sodium Chloride on Pain Relief in Patients with Idiopathic Painful Sensory Neuropathy

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Sorlandet Sykehus HF

Type 2 diabetes mellitus

Not yet recruiting

Study on Switching from Dulaglutide to Tirzepatide for Adults with Type 2 Diabetes

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bromocriptine
  • Sponsor:Eli Lilly Cork Limited

Hyperglycaemia+1

Not yet recruiting

Study on the Safety and Effectiveness of Oral Semaglutide for Patients with High Blood Sugar After Kidney Transplantation

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Region Hovedstaden

Hypoparathyroidism

Not yet recruiting

Study on the Effectiveness and Safety of Eneboparatide in Patients with Chronic Hypoparathyroidism

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alfacalcidol
  • Sponsor:Amolyt Pharma

Diabetic foot

Not yet recruiting

Study Comparing Propylene Glycol and Urea Creams for Treating Dry Feet in People with Diabetes

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Propylene Glycol
  • Sponsor:Malmoe Universitet

Neuroblastoma

Not yet recruiting

Study on the Safety of 68Ga-SATO and Iodine (123I) Iobenguane in Children with Neuroblastoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Satoreotide Trizoxetan Gallium (Ga68)
  • Sponsor:Princess Maxima Center For Pediatric Oncology

Neuroblastoma

Not yet recruiting

Study on Melphalan and Drug Combination for Low and Intermediate Risk Neuroblastoma Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:University Of Cologne

Type 2 diabetes mellitus+3

Not recruiting

A study testing cagrilintide and semaglutide combination for kidney damage in people with chronic kidney disease and type 2 diabetes who are overweight or obese

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Type 2 diabetes mellitus+2

Not recruiting

A Study of Cagrilintide and Semaglutide for Weight Loss in People with Type 2 Diabetes and Overweight or Obesity

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Type 2 diabetes mellitus+2

Not recruiting

Study of Orforglipron for Weight Management in People with Obesity or Overweight, With or Without Type 2 Diabetes

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Sponsor:Eli Lilly & Co.

Substances studied in this area

The therapies tested most often in Endocrine disorders trials.

Semaglutide46 clinical trialsDapagliflozin21 clinical trialsEmpagliflozin14 clinical trialsSodium Chloride13 clinical trialsCisplatin12 clinical trialsEtoposide12 clinical trialsMetformin Hydrochloride12 clinical trialsCarboplatin11 clinical trialsInsulin Glargine11 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.